What Lake Forest Regenesis’s Emsculpt NEO launch reveals about the future of device-led metabolic care
Lake Forest Regenesis launches Emsculpt NEO and Emsella. Discover what this means for noninvasive devices, regulation, and clinical adoption.
Medical Devices & Diagnostics
Pharma & Biotech
FDA approval of milsaperidone puts Vanda Pharmaceuticals into crowded bipolar I disorder and schizophrenia markets
FDA approves milsaperidone for bipolar I disorder and schizophrenia. Explore what this means for psychiatry, competition, and Vanda Pharmaceuticals’ strategy.
Pharma & Biotech
Johnson & Johnson’s three-year TREMFYA data sharpen the durability debate in ulcerative colitis care
Johnson & Johnson’s three-year TREMFYA data highlight why sustained remission is redefining ulcerative colitis treatment decisions. Read the analysis.
Pharma & Biotech
Why YolTech Therapeutics’ YOLT-202 data matters for the future of gene editing in Alpha-1 Antitrypsin Deficiency
Early YOLT-202 data from YolTech Therapeutics suggests gene editing could redefine Alpha-1 Antitrypsin Deficiency treatment. Read the analysis.
Pharma & Biotech
What Enveric Biosciences’ EB-003 data reveal about separating benefit from hallucinations
Enveric Biosciences reports new EB-003 signaling data. Find out what this means for non-hallucinogenic antidepressant development and regulatory risk.
Pharma & Biotech
Can targeting CD36 reshape hepatocellular carcinoma immunotherapy? Pilatus Biosciences takes first step
Pilatus Biosciences earns FDA Fast Track for PLT012 in liver cancer. Read why CD36 targeting could reshape immunotherapy development.
Medical Devices & Diagnostics
Why GE HealthCare’s FDA-cleared SIGNA MRI update is more about operations than image quality
GE HealthCare’s FDA-cleared SIGNA MRI systems signal a shift toward autonomous, helium-free imaging. Explore what this means for MRI operations.
Pharma & Biotech
Why ImmunityBio’s ANKTIVA European launch could reshape BCG-unresponsive bladder cancer care
ImmunityBio expands ANKTIVA into Europe with Accord Healthcare. Discover what this means for bladder cancer care, regulation, and real-world adoption.
Medical Devices & Diagnostics
What Belay Diagnostics’ Summit 2.0 results reveal about the future of CNS molecular diagnostics
Belay Diagnostics validates its Summit 2.0 CSF genomic assay, strengthening the clinical case for liquid biopsy in CNS cancers. Read the full analysis.
Medical Devices & Diagnostics
Why Sibel Health’s Aria sensor could change endpoint design in chronic refractory cough trials
Sibel Health secures FDA acceptance for its Aria cough sensor. Find out what this could change for chronic cough drug trials and digital endpoints.